North America NGS Automation Market to be Worth $776.1 Million by 2030

NGS Automation Market by Product {Workstations, Consumables}, Sequencing Type {Whole Genome, Exome, Targeted Genome}, Application {Drug Discovery, Diagnostics, Oncology}, End User {Hospitals, Pharmaceutical, Diagnostic Labs} - Forecast to 2030

Meticulous Research^®—a leading global market research company, published a research report titled, ‘North America NGS Automation Market by Product {Workstations, Consumables}, Sequencing Type {Whole Genome, Exome, Targeted Genome}, Application {Drug Discovery, Diagnostics, Oncology}, End User {Hospitals, Pharmaceutical, Diagnostic Labs} - Forecast to 2030.’

According to this latest publication from Meticulous Research^®, the North America NGS automation market is expected to register a CAGR of 14% from 2023 to reach $776.1 million by 2030. The growth of the North America NGS automation market is attributed to the increasing prevalence of cancer cases, rising demand for NGS automation in laboratories, growing demand for optimized & streamlined workflows, and increasing pharmaceutical R&D investments & healthcare expenditures. Furthermore, the rising application of NGS technology and collaborations between vendors to develop library preparation protocols are expected to offer immense growth opportunities for market expansion. However, the high cost of automation workstations is expected to restrain the growth of this market to some extent.

Key Players

The key players operating in the North America NGS automation market are Agilent Technologies, Inc. (U.S.), Danaher Corporation (U.S.), Eppendorf AG (Germany), Hamilton Company (U.S.), PerkinElmer, Inc. (U.S.), Tecan Group Ltd. (Switzerland), BRAND GMBH + CO KG (Germany), Hudson Robotics (U.S.), SPT Labtech (U.K.), Thermo Fisher Scientific Inc. (U.S.), and F. Hoffmann-La Roche Ltd. (Switzerland).

North America NGS Automation Market: Future Outlook

The North America NGS automation market is segmented by Product {Workstations/Robotic Platforms, Reagents & Consumables}, Sequencing Type {Whole Genome Sequencing, Whole Exome Sequencing, Targeted Genome Sequencing, Other Sequencing Types}, Application {Drug Discovery, Clinical Diagnostics (Reproductive Health Diagnostics, Oncology Diagnostics, Infectious Disease Diagnostics, Other Clinical Diagnostic Applications), Other Applications}, End User {Pharmaceutical & Biotechnology Companies, Hospitals & Diagnostic Laboratories, Academic & Research Institutes, Other End Users}, and Country. The study also evaluates industry competitors and analyzes their market share at the country level.

Among all the product types studied in the report, in 2023, the workstations/robotic platforms segment is expected to account for the largest share of the North America NGS automation market. The large market share of this segment is attributed to the benefits of automation of NGS for library preparation, such as high efficiency, low turnaround time, reduced per sample cost, high reproducibility over manual methods, and high demand for NGS automation in pharmaceutical & biotechnology companies for drug discovery.

Among all the sequencing types studied in the report, the whole genome sequencing segment is expected to account for the largest share of the North America NGS automation market. The large share of this segment is attributed to the increasing utilization of NGS for identifying novel drug targets and developing therapeutic techniques that target specific genes and proteins, such as targeted therapies, gene therapies, and oligonucleotide therapies.

Among all the applications studied in the report, in 2023, the drug discovery segment is expected to account for the largest share of the North America NGS automation market. The large share of this segment is attributed to the increasing utilization of NGS for identifying novel drug targets and developing therapeutic techniques that target specific genes and proteins, such as targeted therapies, gene therapies, and oligonucleotide therapies.

Among all the end users studied in the report, the pharmaceutical and biotechnology companies segment is expected to account for the largest share of the North America NGS automation market in 2023. The large share of this segment is attributed to the rising R&D expenditure and the growing demand for new drug discoveries using advanced technologies.

Among all the countries studied in the report, the U.S. is expected to account for the largest share of the North America NGS automation market in 2023. The large market share of the U.S. is attributed to the increasing R&D expenditure by the pharma & biotech industry, the presence of leading NGS automation platform providers in the region, favorable government initiatives for genomics research, growing applications of NGS-based research, rising awareness of NGS-based tests, increasing cancer prevalence, and favorable reimbursement scenario in the country.

Download Sample Report Here @ https://www.meticulousresearch.com/download-sample-report/cp_id=5736

Key questions answered in the report:

What are the high-growth market segments regarding the product, sequencing type, application, end user, and country?
What was the historical market for North America NGS automation?
What are the market forecasts and estimates for 2023–2030?
What are the major drivers, restraints, challenges, and opportunities in the North America NGS automation market?
Who are the major players in the North America NGS automation market?

Contact Us:
Meticulous Research®
Email- sales@meticulousresearch.com
Contact Sales- +1-646-781-8004
Connect with us on LinkedIn- https://www.linkedin.com/company/meticulous-research